Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Capital Expenditures (2016 - 2024)

Fortress Biotech has reported Capital Expenditures over the past 11 years, most recently at -$1.4 million for Q3 2024.

  • Quarterly results put Capital Expenditures at -$1.4 million for Q3 2024, down 139600.0% from a year ago — trailing twelve months through Sep 2024 was $28000.0 (down 77.78% YoY), and the annual figure for FY2023 was $63000.0, down 97.68%.
  • Capital Expenditures for Q3 2024 was -$1.4 million at Fortress Biotech, down from $1.4 million in the prior quarter.
  • Over the last five years, Capital Expenditures for FBIO hit a ceiling of $1.6 million in Q2 2022 and a floor of -$1.4 million in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $63500.0 (2022), compared with a mean of $226611.1.
  • Peak annual rise in Capital Expenditures hit 8618.75% in 2024, while the deepest fall reached 139600.0% in 2024.
  • Fortress Biotech's Capital Expenditures stood at -$1.2 million in 2020, then decreased by 11.86% to -$1.3 million in 2021, then skyrocketed by 106.8% to $91000.0 in 2022, then crashed by 69.23% to $28000.0 in 2023, then plummeted by 5082.14% to -$1.4 million in 2024.
  • The last three reported values for Capital Expenditures were -$1.4 million (Q3 2024), $1.4 million (Q2 2024), and $28000.0 (Q4 2023) per Business Quant data.